Skip to main content

Table 1 Clinical features of AML patients according to UGT1A1 genotypes

From: Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens

Clinical features

Total (n = 726)

UGT1A1*28

UGT1A1*6

*1/*1 (n = 579)

*28/− (n = 147)

P value

*1/*1 (n = 493)

*6/− (n = 233)

P value

Age, years

41 ± 14

41 ± 14

41 ± 15

0.816

41 ± 14

42 ± 14

0.799

Male sex, n (%)

400 (55.1)

317 (54.7)

83 (56.5)

0.709

280 (56.8)

120 (51.5)

0.181

Smoking, n (%)

171(23.6)

141 (24.4)

30 (20.4)

0.314

125 (25.4)

46 (19.7)

0.096

Drinking, n (%)

108 (14.9)

91 (15.7)

17 (11.6)

0.206

69 (14.0)

39 (16.7)

0.332

FAB classification, n (%)

 M0

3 (0.4)

2 (0.3)

1 (0.7)

0.918

1 (0.2)

2 (0.9)

0.204

 M1

38 (5.2)

10 (5.2)

11 (7.5)

 

33 (6.7)

8 (3.4)

 

 M2

372 (51.2)

298 (51.5)

74 (50.3)

 

258 (52.3)

114 (48.9)

 

 M4

149 (20.5)

118 (20.4)

28 (19.0)

 

94 (19.1)

52 (23.3)

 

 M5

146 (20.1)

117 (20.2)

29 (19.7)

 

97 (19.7)

49 (21.0)

 

 M6

17 (2.3)

13 (2.2)

4 (2.7)

 

9 (1.8)

8 (3.4)

 

 M7

1 (0.1)

1 (0.2)

–

 

1 (0.2)

–

 

AML type, n (%)

 De novo AML

692 (95.3)

551 (95.2)

141 (95.9)

0.699

469 (95.1)

223 (95.7)

0.732

 Secondary AML

34 (4.7)

28 (4.8)

6 (4.1)

 

24 (4.9)

10 (4.7)

 

Parameters at diagnosis

 WBC count, × 109/l

40.07 ± 62.15

39.54 ± 62.53

42.17 ± 60.80

0.650

40.70 ± 59.07

38.72 ± 68.37

0.691

 RBC count, × 1012/l

2.33 ± 1.64

2.26 ± 0.77

2.60 ± 3.33

0.232

2.39 ± 1.93

2.21 ± 0.73

0.173

 Hemoglobin, g/l

73.98 ± 21.68

73.64 ± 21.86

75.36 ± 20.99

0.395

74.61 ± 22.25

72.66 ± 20.44

0.261

 Platelets count, × 109/l

55.41 ± 64.40

54.70 ± 60.73

58.22 ± 77.45

0.559

53.90 ± 61.17

58.62 ± 70.80

0.360

 Neutrophil count, × 109/l

13.44 ± 33.00

13.51 ± 34.56

13.14 ± 26.04

0.905

13.98 ± 32.47

12.29 ± 34.23

0.525

 LDH, U/l

564.6 ± 725.2

561.2 ± 771.9

578.2 ± 501.1

0.806

566.4 ± 758.5

560.9 ± 651.7

0.926

 Bone marrow blasts, %

65.37 ± 20.88

64.94 ± 20.81

67.02 ± 21.12

0.291

65.98 ± 21.21

64.08 ± 20.15

0.267

Risk stratifications, n (%)

 Low risk

152 (20.9)

115 (19.9)

37 (25.2)

0.553

98 (19.9)

54 (23.2)

0.142

 Intermediate risk

330 (45.5)

267 (46.1)

63 (42.9)

 

230 (46.7)

100 (42.9)

 

 High risk

140 (19.3)

114 (19.7)

26 (17.7)

 

102 (20.7)

38 (16.3)

 

 Unknown

104 (14.3)

83(14.3)

21 (14.3)

 

63 (12.8)

41 (17.6)

 

HSCT, n (%)

124 (17.1)

94 (16.2)

30 (20.4)

0.230

89 (18.1)

35 (15.0)

0.311

  1. *28/− or *6/− represents mutant homozygous and heterozygous of corresponding loci on UGT1A1
  2. Risk stratification based on NCCN guidelines version 1.2015 acute myeloid leukemia
  3. FAB Classification French–Britain–American Classification, HSCT hematopoietic stem cell transplantation, LDH lactate dehydrogenase, RBC red blood cell, WBC white blood cell
  4. P value was based on χ2 test for categorical variables and student’s t test for continuous variables
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us